Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

Misleading ads on social media are promoting products that doctors say are not effective but mimic the names of more ...

A growing number of obese adults and children have been prescribed Ozempic or similar medications to lose weight ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Weight-loss drugs among breakthrough trials offering ‘hope’ for dementia prevention - One clinical trial is assessing whether ...

According to the Mayo Clinic, most weight loss occurs within the first four to five months of use. Long-term use of weight loss drugs can lead to sustained weight decreases and improvements in overall ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

The supply of GLP-1 drugs like Ozempic has been increasing, but they’re still expensive for most patients. Here are answers ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Hims Hers Health Inc (NYSE:HIMS), a telehealth firm known for offering consumer-focused digital healthcare, is reducing its headcount by more than 4% as part of a pivot in its business strategy, ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...